The study and its comparison
CREST-E randomized 553 adults with early symptomatic Huntington’s disease at forty-six sites. Creatine monohydrate or placebo was given for up to forty-eight months, with total functional capacity as the primary endpoint. [1]
The study stopped for futility before reaching planned enrollment. Functional decline was not reduced by creatine. Gastrointestinal adverse events were more common with creatine, while serious adverse events were more frequent with placebo. [1]
What the finding establishes
Keeping both adverse-event findings avoids equating every side effect with serious harm. The trial does not establish that a higher creatine amount protects neurons or preserves everyday function. Funding and complete conflicts were not established from the abstract. Disease-specific findings should remain separate from sports-nutrition claims or assumptions about using creatine without exercise. [1]
A hypothetical distinction
Imagine mild gastrointestinal events increase while serious events do not. Those safety categories should not be combined into one rate.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- The CREST-E study of creatine for Huntington disease: A randomized controlled trial.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.